Sanaria’s CEO Interviewed About Development of a COVID-19 Vaccine
More than 130 labs around the world are working to develop a COVID-19 vaccine. But what would it take to vaccinate everyone by early next year?
Sanaria Recognized for Global Health Partnership in the Fight Against Malaria in BioBuzz
The ultimate goal for Sanaria is eradication of malaria from the planet. What started as a shot in the dark, cold call from Sanaria, has evolved into truly remarkable global health collaboration with Marathon Oil, Noble Energy, AMPCO, and the Government of Equatorial Guinea, that has the potential to fundamentally change the world for the better.
Employee of the Month: Dr. Preston Church
The Sanaria employee of the month for April, 2020 is Dr. Preston Church. Dr. Church is a member of the clinical team and was nominated for employee of the month for his leadership during the COVID crisis.
Sanaria and Protein Potential Recognized for Efforts Against COVID-19 in BioBuzz
Sanaria and Protein Potential, which are co-located in Rockville, Maryland, are working on a number of initiatives to combat COVID-19. Dr. Stephen L. Hoffman is the CEO and Chief Scientific Officer at Sanaria, which is a leading global malaria vaccine biotechnology company. Dr. Kim Lee Sim is the President and Chief Scientific Officer at Protein Potential, an R&D group focused on vaccine development and innovative DNA and protein products. She is also the Executive Vice President of Process Development and Manufacturing at Sanaria.
Employee of the Month: Praise Nyambiya
The Sanaria employee of the month for January 2020 is Praise Nyambiya. Praise is a member of the Quality Systems team and was nominated for employee of the month for his outstanding work in environmental monitoring of the clinical manufacturing facility.
Employees of the Month: Liza Torres-Alvarado and Christopher Carmona
The Sanaria employees of the month for November, 2019 are Liza Torres Alvarado and Christopher Carmona. Liza is a member of the executive team and Christopher is a member of the business development team. Both were co-nominated for employee of the month for their hard work organization and assisting with the 2019 International PfSPZ Consortium Meeting held in Rockville, MD.
i-PfSPZ-C Meets in Rockville, MD on November 18th and 19th, 2019
On 18 and 19 November 2019, Sanaria hosted the semi-annual International PfSPZ Consortium (i-PfSPZ-C) meeting at the University of Maryland Institute for Bioscience and Biotechnology Research in Rockville, MD.
Sanaria Attended the 68th ASTMH Meeting
From 20-24 November 2010, Sanaria participated in the 68th Annual ASTMH (American Society of Tropical Medicine and Hygiene) Meeting held at the Gaylord Resort in Washington, D.C.
Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults
A vaccine would be an ideal tool for reducing malaria's impact. PfSPZ Vaccine (radiation attenuated, aseptic, purified, cryopreserved Plasmodium falciparum [Pf] sporozoites [SPZ]) has been well tolerated and safe in >1,526 malaria-naïve and experienced 6-month to 65-year-olds in the U.S., Europe, and Africa.
Employee of the Month: Urvashi Rai
The Sanaria employee of hte month for October, 2019 is Urvashi Rai. Urvashi is a scientist in the Department of Vaccine Extraction, Immunology and Models Systems (VIEMS). Urvashi was nominated for employee of the month to recognize her dedication in training the part-time vaccine extraction specialists.
Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial
Ivermectin is safe and widely used for treating helminth infections. It also kills arthropods feeding on treated subjects, including malaria vectors. Thus, ivermectin mass drug administration as an additional tool for malaria control is being evaluated by WHO. As in vitro data, animal experiments and epidemiological observations suggest that ivermectin has a direct effect on the liver stages of the malaria parasite, this study was designed to assess the prophylactic effect of ivermectin on Plasmodium falciparum controlled human malaria infection.
Dose-Dependent Infectivity of Aseptic, Purified, Cryopreserved Plasmodium falciparum 7G8 Sporozoites in Malaria-Naive Adults
We conducted a double-blind, randomized, dose-escalation study to assess the infectivity of the 7G8 clone of Pf (PfSPZ Challenge [7G8]). Results showed dose-dependent infectivity from 43% for 8 × 102 PfSPZ to 100% for 4.8 × 103 PfSPZ. PfSPZ Challenge (7G8) will allow for more complete assessment by CHMI of antimalarial vaccines and drugs.
Activation of TCR Vδ1+ and Vδ1-Vδ2- γδ T Cells upon Controlled Infection with Plasmodium falciparum in Tanzanian Volunteers
Our understanding of the human immune response to malaria remains incomplete. Clinical trials using whole-sporozoite-based vaccination approaches such as the Sanaria PfSPZ Vaccine, followed by controlled human malaria infection (CHMI) to assess vaccine efficacy offer a unique opportunity to study the immune response during Plasmodium falciparum infection.
Sanaria Celebrates Diwali
Diwali, Deepavali or Dipavali is an Indian festival of lights, which is celebrated every autumn. One of the most popular festivals in India, Diwali symbolises the “victory of light over darkness, good over evil and knowledge over ignorance.” Light is a metaphor for knowledge and consciousness. During the celebration the houses, the streets are decorated with lights. People invite friends and families and celebrate together with good foods, by exchanging gifts and burning the fire crackers. Sanaria and Protein Potential celebrated today with song, dance, and delicious food!|
Employee of the Month: Joe Rosati
The Sanaria employee of the month for September, 2019 is Joe Rosati. Joe is the head of the facilities team and was nominated for employee of the month for outstanding work repairing and maintaining our facilities and equipment.
Prof. Shahid Kahn, Long Time Sanaria Collaborator and Friend, Passes
It is with great sadness that Sanaria shares the news of the passing of our long-standing collaborator and friend, Professor Shahid Khan.
Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2
GMZ2 is well tolerated and immunogenic in lifelong-Pf-exposed adults from Gabon, with similar antibody responses regardless of formulation. CHMI showed no protective effect of prior vaccination with GMZ2, although baseline, vaccine-specific antibody concentrations were associated with protection. CHMI with the PfSPZ Challenge is a potent new tool to validate asexual, blood-stage malaria vaccines in Africa.
Sanaria and its Bioko Island Malaria Elimination Project partners win the Concordia P3 Impact Award and Audience Choice Award
The Bioko Island Malaria Elimination Project (BIMEP) is a long-term partnership dedicated since 2004 to the elimination of malaria from Equatorial Guinea which had one of the highest rates of malaria transmission and where the disease was the leading cause of morbidity and mortality.
Sanaria Symposium at the European Congress on Tropical Medicine and International Health
On Thursday 19 September, a symposium entitled “PfSPZ vaccines: Phase 3 to licensure to deployment and use in elimination campaigns” was held at the European Congress on Tropical Medicine and International Health in Liverpool, U.K.
Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross
Mainstay treatment for Plasmodium vivax malaria has long relied on chloroquine (CQ) against blood-stage parasites plus primaquine against dormant liver-stage forms (hypnozoites), however drug resistance confronts this regimen and threatens malaria control programs.
